• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,113
103
69
68
65

COUNTRY

63
19
16
10
9

CATEGORIES

  • 88
  • 127
  • 68
  • 74
  • 43
  • 42
  • 20
  • 17
  • 18
  • 22

PRICE

563
809
1,568
2,551

PUBLISHED

78
137
709
2,551

PRODUCT TYPE

2,406
70
61
12
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Oncology Pipeline Database Oncology Pipeline Database - Product Thumbnail Image

Oncology Pipeline Database

Subscription "Oncology Pipeline Database" provides online access to more than 3,000 project entries in oncology Each project is specified for its Target or Mechanism of Action, Product Category and...

October 2014
FROM

Hematology

6 issues per year Hematology is an international journal, publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology...

October 2014
FROM
Future Oncology: Technology, Products, Market and Service Opportunities Future Oncology: Technology, Products, Market and Service Opportunities - Product Thumbnail Image

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology is an analytical newsletter for executives, researchers, and market analysts in the pharmaceutical, biotechnology, financial, hospital and other health care industries. It provides comprehensive,...

October 2014

Global Pancreatic Cancer Market 2014-2018

About Pancreatic Cancer Pancreatic cancer is a malignant cells form in the tissues of pancreas. Based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine...

October 2014
FROM
Drug Delivery in Cancer - Technologies, Markets and Companies Drug Delivery in Cancer - Technologies, Markets and Companies - Product Thumbnail Image

Drug Delivery in Cancer - Technologies, Markets and Companies

Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery...

October 2014
FROM

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014 Summary This, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014’, provides an overview of the Metastatic Hepatocellular...

September 2014
FROM

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014 Summary This, ‘Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014’, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)’s...

September 2014
FROM

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014 Summary This, ‘Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014’, provides an overview of the Waldenstrom Macroglobulinemia’s therapeutic...

September 2014
FROM

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2014

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2014 Summary This, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) -...

September 2014
FROM

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer)...

September 2014
FROM

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer)...

September 2014
FROM

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) -...

September 2014
FROM

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

Hairy Cell Leukemia - Pipeline Review, H2 2014

Hairy Cell Leukemia - Pipeline Review, H2 2014 Summary This, ‘Hairy Cell Leukemia - Pipeline Review, H2 2014’, provides an overview of the Hairy Cell Leukemia’s therapeutic pipeline. This report...

September 2014
FROM

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014 Summary This, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014’, provides an overview of the Refractory...

September 2014
FROM
Loading Indicator

Our Clients

Our clients' logos